Longitudinal BLI data indicated CD4+ T cell–dependent efficacy of combined IL-6 and CTLA-4 blockade, as CD4+ T cell–depleted mice receiving therapeutic Abs had accelerated tumor growth progression compared with mice receiving only the combination therapy (Figure 7B). The gene discussed is IL6; the disease is neoplasm.